Vol 8, No 1 (2022)
Review paper
Published online: 2022-04-01
Page views 1850
Article views/downloads 17
Get Citation

Connect on Social Media

Connect on Social Media

Diagnostyka obrazowa w obserwacji chorych na czerniaki skóry i błon śluzowych

Bożena Józefa Cybulska-Stopa1, Grażyna Kamińska-Winciorek2, Piotr Rutkowski3
Forum Dermatologicum 2022;8(1):30-35.

Abstract

W ostatnich latach wyniki leczenia chorych na czerniaki uległy znacznej poprawie. Wiąże się to przede wszystkim z rozwojem nowych metod terapeutycznych, ale również z rozwojem badań obrazowych i rozpoznaniem nawrotu choroby na wczesnym etapie. Dzięki wczesnemu rozpoznaniu nawrotu choroby nowotworowej można zastosować właściwą terapię, która w wielu przypadkach może doprowadzić do całkowitego wyleczenia.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Dinnes J, Ferrante di Ruffano L, Takwoingi Y, et al. Cochrane Skin Cancer Diagnostic Test Accuracy Group. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Database Syst Rev. 2019; 7: CD012806.
  2. Rutkowski P, Wysocki PJ, Kozak K, et al. Expert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Pract. Oncol Clin Pract. .
  3. Danielsen M, Højgaard L, Kjær A, et al. Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging. 2013; 4(1): 17–28.
  4. Nijhuis AAG, Dieng M, Khanna N, et al. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Ann Surg Oncol. 2019; 26(6): 1860–1868.
  5. Koskivuo I, Kemppainen J, Giordano S, et al. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma. Acta Oncol. 2016; 55(11): 1355–1359.
  6. Vensby PH, Schmidt G, Kjær A, et al. The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging. 2017; 7(6): 255–262.
  7. Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol. 2009; 16(3): 571–577.
  8. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cutaneous melanoma. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (23.08.2021).
  9. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005; 6(8): 608–621.
  10. Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg. 2008; 95(11): 1401–1407.
  11. Trotter SC, Sroa N, Winkelmann RR, et al. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol. 2013; 6(9): 18–26.
  12. Atkins MB, Long GV, Warneke CL, et al. Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study. J Clin Oncol 28:15s, 2010 (suppl; abstr. ; 8516.
  13. Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007; 14(6): 1924–1933.
  14. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004; 351(10): 998–1012.
  15. Bassères N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology. 1995; 191(3): 199–203.
  16. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer. 2003; 97(3): 639–643.
  17. DiFronzo LA, Wanek LA, Elashoff R, et al. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999; 6(7): 705–711.
  18. Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med . 2017; 376(12): 2211–2222.
  19. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995; 221(5): 566–9; discussion 569.
  20. Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009; 16(4): 941–947.
  21. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995; 274(21): 1703–1705.
  22. Ward WH, Farma JM. editors. Cutaneous Melanoma: Etiology and Therapy [Internet] . Codon Publ. 2017: Codon.
  23. Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003; 21(3): 520–529.
  24. Podlipnik S, Carrera C, Sánchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol. 2016; 75: 516.
  25. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010; 28(18): 3042–3047.
  26. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14(1): 7–17.
  27. DeRose ER, Pleet A, Wang W, et al. Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res. 2011; 21(4): 364–369.
  28. Turner RM, Dieng M, Khanna N, et al. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma. Ann Surg Oncol. 2021; 28(8): 4561–4569.